Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to validate the long-term benefit of denosumab for osteoporosis
treatment in a real-world clinical practice setting. We hypothesize that continued therapy
(36+months) with denosumab will increase both trabecular bone score (TBS) and femur strength
index (FSI) and reduce fracture and other bone health risks among post-menopausal women with
osteoporosis.